Ignite Creation Date:
2024-05-06 @ 6:05 PM
Last Modification Date:
2024-10-26 @ 2:41 PM
Study NCT ID:
NCT05548088
Status:
UNKNOWN
Last Update Posted:
2022-09-21
First Post:
2022-09-16
Brief Title:
LILRB4 STAR-T Cells in the Treatment of RelapsedRefractory Acute Myeloid Leukemia
Sponsor:
Peking University Peoples Hospital
Organization:
Peking University Peoples Hospital
Study Overview
Official Title:
An Exploratory Clinical Study on the Safety and Efficacy of LILRB4 STAR-T Cells in the Treatment of RelapsedRefractory Acute Myeloid Leukemia RR AML
Status:
UNKNOWN
Status Verified Date:
2022-09
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single-center single-arm open-label phase I clinical study to determine the safety and efficacy of LILRB4 STAR-T cells in RelapsedRefractory Acute Myeloid Leukemia subjects
Detailed Description:
This study will recruit LILRB4 positive AML subjectsand Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5 -4 and -3 followed by infusion of LILRB4 STAR-T cells LILRB4 STAR-T cells will be intravenously infused with a escalated dose of 1E63E66E61E7 cellskgThe purpose of current study is to evaluate the clinical safety and tolerability of LILRB4 STAR-T cells therapy in patients with refractory and relapsed AMLSafety and efficacy of LILRB4 STAR-T cells therapy will be monitoredThe primary endpoint of the study is to observe DLT AE SAE CRS and ICANS Secondary objectives are to observe the efficacy of LILRB4 STAR-T cells including RFS EFS and OS and PK
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None